Satellos Bioscience Inc.
MSLE
$7.28
$0.020.28%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -20.54% | -4.98% | -34.12% | -38.21% | -75.43% |
| Total Depreciation and Amortization | -73.33% | 73.33% | 55.84% | 118.75% | 194.12% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -11.83% | -63.80% | 149.89% | 51.79% | 7.80% |
| Change in Net Operating Assets | -96.28% | -295.63% | -363.91% | -1,316.02% | -385.34% |
| Cash from Operations | -29.28% | -44.73% | -41.20% | -51.79% | -112.26% |
| Capital Expenditure | -50.00% | -27.66% | 75.41% | 79.17% | 70.15% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -301.95% | -2,292.42% | 202.10% | 142.31% | 136.19% |
| Cash from Investing | -302.26% | -2,307.66% | 201.97% | 142.25% | 136.12% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -92.69% | 1,035.60% | 1,087.51% | -12.80% | -12.80% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 316.63% | 344.76% | -55.37% | -55.40% |
| Cash from Financing | -94.04% | 15,170.99% | 2,110.84% | 4.77% | 0.11% |
| Foreign Exchange rate Adjustments | 185.84% | 83.54% | 178.27% | 51.55% | 31.01% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -229.40% | 112.42% | 206.49% | 211.22% | 53.98% |